Drug-Radiotherapy Combination Trial Developments-Letter

We read with great interest the comprehensive review by Chargari and colleagues about the challenges of advancing new radiosensitizing drugs through preclinical models and clinical trials ([1][1]). The authors laid out a number of explanations and recommendations for moving forward with more success